Trial Profile
A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Tetracosactide (Primary) ; Vigabatrin
- Indications Infantile spasms
- Focus Therapeutic Use
- 26 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.
- 24 Sep 2019 Status changed from recruiting to suspended.
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.